Navigation Links
ViroPharma Announces Positive CHMP Opinion for Cinryze® (C1 Inhibitor [Human]) in European Union
Date:3/18/2011

verely affected HAE patients. It is also beneficial that this C1-inhibitor therapy is also to be approved for therapy of acute attacks and pre-procedure prevention."

"This positive CHMP opinion marks a key step in making Cinryze available to HAE patients across Europe and beyond that choose to proactively address their disease," commented Thierry Darcis, M.D., ViroPharma's vice president, general manager, Europe.  "We estimate that there are several thousand patients throughout Europe who suffer from this debilitating disease, and with this recommendation, these patients may soon benefit from the unique use of Cinryze to either prevent their attacks or treat them when they occur, with the added convenience of self administration after appropriate training.  ViroPharma is committed to providing important medicines to patients with unmet medical needs, and we look forward to working closely with physicians across Europe toward this important goal."

The CHMP is the scientific advisory body of the EMA responsible for reviewing Marketing Authorization Applications for medicinal products for human use.  The CHMP positive opinion forms the scientific basis for the European Commission to issue a binding decision for a Centralized Marketing Authorization, once issued, is valid throughout all the Member States of the European Union (EU) as well as in the European Economic Area (EEA), namely Norway, Iceland and Liechtenstein. The anticipated timeframe for the European Commission decision is in the second quarter of 2011.  A summary of the CHMP opinion will be available here: http://tinyurl.com/2am4ubc.  Please select "C" to access the Cinryze summary opinion.

Continued Darcis, "Our work is already well underway towards preparing for our commercial launch in Europe, with the goal of making this important therapeutic product available to European patients as soon as possible."

Cinryze w
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ViroPharma to Present at Three Upcoming Healthcare Conferences
2. ViroPharma to Present at the Natixis Bleichroeder Conference
3. ViroPharma To Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
4. ViroPharma to Release 2008 First Quarter Financial Results on April 30, 2008
5. ViroPharma Announces Discontinuation of HCV-796 Development
6. ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients
7. ViroPharma Incorporated Completes Acquisition of Lev Pharmaceuticals
8. ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema
9. ViroPharma Announces Discontinuation of Maribavir Phase 3 Study in Liver Transplant Patients
10. ViroPharma Submits Comments on Vancocin(R) Draft Bioequivalence Guidance
11. ViroPharma Incorporated Reports Third Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... 04, 2015 Research ... addition of the "Pharmacovigilance (London, UK - ... Understanding PhV today - the principles ... in Drug safety. This course aims ... pharmacovigilance. New entrants as well as experienced operators ...
(Date:9/4/2015)... , Sep. 04, 2015 ... ) has announced the addition of the ... Market, 2010-2019" report to their offering. ... polymer containing repeating disaccharide units of Na-glucuronate-N-acetylglucosamine. ... and cartilage matrix, sodium hyaluronate can lubricate ...
(Date:9/3/2015)... Report Details Ovarian Cancer ... Changes and Emerging Opportunities What,s the future for ... study forecasts those pharmaceutical revenues. There you find ... also explore trends, results, treatments, R&D, and opportunities, ... predictions to 2025 at overall world market, submarket, ...
Breaking Medicine Technology:Pharmacovigilance Course: The Principles and Practice of Global PhV for those Working in Drug Safety (London, UK - December 7-9, 2015) 2Investigation Report on China's Sodium Hyaluronate Market 2015 2Ovarian Cancer Drug Therapy: Companies, R&D and Revenue Forecasts 2015-2025: Recently Approved Treatments Give High Market Potential 2Ovarian Cancer Drug Therapy: Companies, R&D and Revenue Forecasts 2015-2025: Recently Approved Treatments Give High Market Potential 3Ovarian Cancer Drug Therapy: Companies, R&D and Revenue Forecasts 2015-2025: Recently Approved Treatments Give High Market Potential 4Ovarian Cancer Drug Therapy: Companies, R&D and Revenue Forecasts 2015-2025: Recently Approved Treatments Give High Market Potential 5Ovarian Cancer Drug Therapy: Companies, R&D and Revenue Forecasts 2015-2025: Recently Approved Treatments Give High Market Potential 6
... 23, 2011 ViewRay™, Inc., a privately held ... clearance for its radiotherapy treatment planning and delivery ... the company,s new radiation therapy system, which combines ... in the late stages of development, the integrated ...
... Inc. (Nasdaq: NBIX ) announced today that Kevin ... be presenting at Citi,s 2011 Global Health Care Conference in ... place on Tuesday, March 1, 2011 at 2:00 p.m. Eastern ... webcast and may be accessed on the Company,s website at ...
Cached Medicine Technology:ViewRay Receives FDA 510(k) Marketing Clearance for Treatment Planning and Delivery Software 2
(Date:9/4/2015)... (PRWEB) , ... September 04, 2015 , ... The Schmidt ... of Tanya De La Paz. , Schmidt National Law Group, a leading firm ... District of California against Bayer Corp., Bayer Essure, Inc., and other Bayer affiliates for ...
(Date:9/4/2015)... (PRWEB) , ... September 04, 2015 , ... ... Consumer Health Products Association (CHPA) joint meeting of its Product, Quality and Manufacturers, ... hazardous waste handling rules constantly evolving in the consumer goods industry, it can ...
(Date:9/4/2015)... ... September 04, 2015 , ... “Getting away from the daily ... to explore, revitalize and strengthen their ‘couple-ness,’” says Jean Claude Wietzel, general manager ... Seasons Resort Maui, the island’s only Forbes Five Star resort and Travel + Leisure’s ...
(Date:9/4/2015)... Portland, ME (PRWEB) , ... September 04, 2015 ... ... Symposium focus on: the microbiome taking place in Hollywood, Florida October 9-10, 2015 ... ihsymposium.com/focus-event. , Speakers at the 2015 symposium are doctors and researchers at the ...
(Date:9/4/2015)... , ... September 04, 2015 , ... ... pale in comparison to settlements under the Stark physician self-referral law. “Stark ... Sept. 17 webinar from Atlantic Information Services, Inc. (AIS), will detail which deals ...
Breaking Medicine News(10 mins):Health News:Schmidt National Law Group Files First Bayer Essure® Lawsuit in California 2Health News:Inmar Experts To Address OTC Manufacturers’ Session on Hazardous Waste and Handling at CHPA Meeting 2Health News:Inmar Experts To Address OTC Manufacturers’ Session on Hazardous Waste and Handling at CHPA Meeting 3Health News:Couples Season at Four Seasons Resort Maui Begins This Week With Best Hotel Rates of the Year through November 2Health News:Couples Season at Four Seasons Resort Maui Begins This Week With Best Hotel Rates of the Year through November 3Health News:Integrative Healthcare Symposium Focus On: The Microbiome Conference Program Announced 2Health News:Sept. 17 Webinar to Offer Best Practices for Physician Contracts 2
... B1) states that a deficiency in vitamin B1 could ... treat obesity//. This is based on a study published ... of Neurology. ,The study further elucidates ... Wernicke’s encephalopathy, a severe neurological condition. ,Women ...
... or sell Viagra, as they fear it may result in ... ,"We will not sale the drug as it may lead ... problems," said Amar Sinha, general secretary of the Jharkhand Chemist ... added: "The common practice here is to sell medicines even ...
... Resorts has banned smoking in the rooms, restaurants, bars and ... and the Caribbean from January 2006//., ,Guests will only ... areas. , ,Westin said research among its customers had ... , ,"Nobody likes to walk into a smoky guest ...
... an Arizona-based biotech company is testing out OraTest, its detection ... is a disfiguring entity // that is caused by chewing ... that nearly 30,000 people are diagnosed with oral cancer every ... into perspective when he said, "We are subduing the dangers ...
... at the Picower Institute for Learning and Memory shows that neurons ... earlier concept of adult brain // lacks the capacity to grow ... avenues to research on the various techniques that could induce growth ... like the genetic or the sensory or by other ways that ...
... conducted by Crimmins and Finch showed the effect of ... of developing cardiovascular diseases // . ,They ... Sweden, France, England and Switzerland from different years but ... 1900 modern medicine was an important factor in treating ...
Cached Medicine News:Health News:More The Usage More The Growth In The Adult Brain. 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: